Core Insights - Ryder System, Inc. has consistently rewarded shareholders through dividends and share buybacks, with a total return of $456 million in 2024 and $71 million in dividends along with $261 million in share repurchases in the first half of 2025 [1][10] Dividend Policy - On July 10, 2025, Ryder's board approved a 12% increase in its quarterly cash dividend, raising it to 91 cents per share from 81 cents, reflecting the company's commitment to enhancing shareholder returns [2][5] - This dividend hike is the first since July 2024, marking Ryder's 196th consecutive quarterly cash dividend and demonstrating over 49 years of uninterrupted dividend payments [3][10] Market Position and Performance - Ryder's stock has shown strong performance, improving in double digits over the past year and outperforming the Zacks Transportation - Equipment and Leasing industry [9] - The stock is currently trading at a forward 12-month price-to-sales ratio of 0.57X, significantly lower than the industry average of 1.94X, indicating an attractive valuation [13] Industry Context - Other companies in the transportation sector, such as Kirby Corporation and Werner Enterprises, have also engaged in share buyback programs in 2025, reflecting a broader trend of returning capital to shareholders [6][7] - Union Pacific Corporation has similarly increased its dividend by 3%, showcasing a commitment to shareholder returns within the industry [8]

Core Viewpoint - Theralase Technologies Inc. has announced the peer-reviewed publication of preclinical data demonstrating that its antiviral candidate Ruvidar® is more effective than Acyclovir® and Metformin® in treating Herpes Simplex Virus Type 1 (HSV-1) [1][2][3] Company Summary - Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on developing light, radiation, sound, and drug-activated therapeutics for treating various diseases, including cancer and viral infections [1][8] - The company is advancing Ruvidar® into clinical development, with plans for a Phase I/II adaptive clinical study in 2026 to assess its safety and efficacy in treating cold sore lesions [1][6] Research Findings - The latest research published in MDPI - Viruses indicates that Ruvidar® significantly inhibits HSV-1 replication post-infection, unlike Acyclovir® and Metformin®, which show little effect once infection is established [2][3] - Ruvidar® has demonstrated effectiveness against Acyclovir®-resistant HSV-1 mutants, highlighting its potential as a next-generation antiviral therapy [3][4] - The combination of Ruvidar® with Acyclovir® proved to be more effective than either treatment alone, suggesting potential for combinational therapies [4][6] Market Context - The global HSV treatment market was estimated at $2.8 billion in 2024 and is projected to grow to $4.7 billion by 2033, indicating a significant opportunity for effective antiviral treatments like Ruvidar® [8]

Core Viewpoint - Zomedica Corp. has expanded its TRUFORMA diagnostic platform to include feline testing capabilities for its cobalamin and folate assay, marking a significant advancement in veterinary diagnostics [1] Group 1: Product Development - The TRUFORMA diagnostic platform now offers a multiplexed assay that combines cobalamin and folate testing, which was previously available only for canine patients [1] - This assay is the first of its kind to provide both cobalamin and folate testing in an in-clinic setting, enhancing the diagnostic capabilities for veterinarians [1] Group 2: Market Position - Zomedica is positioned as an innovative veterinary health company focused on point-of-care diagnostic and therapeutic device products for both equine and companion animals [1]

Core Viewpoint - The Zacks Transportation - Equipment and Leasing industry is facing a challenging macroeconomic environment characterized by persistent inflation, tariff-related tensions, and supply-chain disruptions, alongside geopolitical issues [1][5]. Industry Overview - The industry encompasses companies that provide equipment financing, leasing, and supply-chain management services, including aircraft, railcar, and intermodal container lessors. It also includes logistics and transportation solutions for a diverse customer base, primarily in automotive, electronics, transportation, grocery, lumber, food service, and home furnishing sectors [3]. Financial Performance and Shareholder Returns - Companies like Wabtec Corporation and Ryder System are noted for their shareholder-friendly initiatives, such as dividend payouts and share buybacks, indicating strong financial health. Ryder recently approved a 12% dividend increase, raising its quarterly cash dividend to 91 cents per share, while Wabtec announced a 25% increase, raising its quarterly cash dividend from 20 cents to 25 cents [2][4]. Economic Challenges - The industry is grappling with ongoing tariff tensions and inflation, which contribute to economic uncertainty and may hinder stock performance. Supply-chain disruptions and rising operating costs are also limiting growth potential [5][6]. Industry Ranking and Performance - The Zacks Transportation - Equipment and Leasing industry holds a Zacks Industry Rank of 75, placing it in the top 31% of over 250 Zacks industries. However, it has underperformed compared to the S&P 500 and the broader sector over the past year, declining 18.4% against the S&P 500's increase of 18.7% [7][9][10]. Current Valuation - The industry is currently trading at a forward 12-month price-to-earnings (P/E) ratio of 13.99X, which is lower than the S&P 500's 23.52X and the sector's 13.84X. Historically, the industry has traded between 8.42X and 15.65X over the past five years [13]. Notable Companies to Watch - **Wabtec Corporation**: Focused on technology-based locomotives and services, Wabtec has shown strong earnings performance, with a 17.6% expected earnings growth rate for 2025 [17][19]. - **Ryder System**: A logistics and transportation company with a long history of dividend payments, Ryder has an expected earnings growth rate of 9.3% for 2025 [22][23]. - **The Greenbrier Companies**: Specializing in railroad freight car equipment, Greenbrier has a notable earnings surprise history and an expected earnings growth rate of 33.1% for 2025 [26][28].

MARKHAM, ON / ACCESS Newswire / September 22, 2025 / iFabric Corp. ("iFabric" or the "Company") (TSX:IFA)(OTCQX:IFABF) today announced that its wholly owned subsidiary, Intelligent Fabric Technologies (North America) Inc. ("IFTNA"), has renewed its license agreement with TUMI, Inc. ("TUMI") to continue integrating IFTNA's PROTX2® antimicrobial solutions across select TUMI products. The renewal extends the relationship first announced on May 5, 2021, by a further period of five years. ...

Inverite Achieves Milestone SOC 2(R) Type II Audit Validation and Data Security ControlsSeptember 18, 2025 8:00 AM EDT | Source: Inverite Insights Inc.Vancouver, British Columbia--(Newsfile Corp. - September 18, 2025) - Inverite Insights Inc. (CSE: INVR) (OTC Pink: INVRD) (FSE: 2V0) ("Inverite") is a leading AI-driven software provider utilizing real-time financial data to empower businesses to transact more effectively with consumers, today announced it has successfully completed its SOC 2® T ...

Intellectual property portfolio now includes 228 Patents and 153 Trademarks providing robust protection for the Company's product platforms in the rapidly growing multi-billion dollar veterinary diagnostics market ANN ARBOR, MI / ACCESS Newswire / September 18, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced the issuance of four additional ...

IRVINE, CA / ACCESS Newswire / September 15, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it will file a request for supervisory appeal of the not-approvable letter from the Center for Devices and Radiological Health (CDRH) of the U.S. Food & Drug Administration (FDA) received on August 19, 2025, in response to its Premarket Approval (PMA) application for the VenoValve®, a ...

Cutting-Edge Digital Microscopy System Featured in Monthly Series Showcasing Innovation in Veterinary Care ANN ARBOR, MI / ACCESS Newswire / September 12, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering advanced diagnostic and therapeutic solutions for companion and equine animals, is pleased to announce the next installment of its Fourth Friday at Four webinar series, scheduled for Friday, September 26 at 4:00 PM ET, featuring the TRUVIEW digital cyto ...

Core Insights - Horizon Kinetics Holding Corporation upgraded to OTCQX from OTCID™ Basic Market, enhancing its market visibility and trading status [1] Company Summary - Horizon Kinetics Holding Corporation is the holding company for Horizon Kinetics Asset Management LLC [1] - The company began trading on OTCQX under the symbol "HKHC" on September 5th, 2025 [1]